Natalia Jura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/61985/publications.pdf

Version: 2024-02-01

46 papers	7,837 citations	257450 24 h-index	214800 47 g-index
58 all docs	58 docs citations	58 times ranked	14884 citing authors

#	Article	IF	Citations
1	Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Reports, 2022, 38, 110291.	6.4	7
2	Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Reports, 2022, 38, 110285.	6.4	7
3	Efficient expression, purification, and visualization by cryo-EM of unliganded near full-length HER3. Methods in Enzymology, 2022, 667, 611-632.	1.0	0
4	Piquing our interest: Insights into the role of PEAK3 in signaling and disease. Science Signaling, 2022, 15, eabm9396.	3.6	3
5	Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature, 2022, 602, 487-495.	27.8	237
6	An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1Î² heterocomplex and cryo-EM structure determination at low sample concentrations. Methods in Enzymology, 2022, 667, 633-662.	1.0	2
7	CNPY4 inhibits the Hedgehog pathway by modulating membrane sterol lipids. Nature Communications, 2022, 13, 2407.	12.8	3
8	Expression and purification of active human kinases using Pichia pastoris as a general-purpose host. Protein Expression and Purification, 2021, 179, 105780.	1.3	1
9	Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Communications Biology, 2021, 4, 475.	4.4	126
10	A survey of the kinome pharmacopeia reveals multiple scaffolds and targets for the development of novel anthelmintics. Scientific Reports, 2021, 11, 9161.	3.3	5
11	State of the structure address on MET receptor activation by HGF. Biochemical Society Transactions, 2021, 49, 645-661.	3.4	5
12	Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking. Science Advances, 2021, 7, .	10.3	100
13	Mutant HER2 needs mutant HER3 to be an effective oncogene. Cell Reports Medicine, 2021, 2, 100361.	6.5	2
14	Structural basis for ALK2/BMPR2 receptor complex signaling through kinase domain oligomerization. Nature Communications, 2021, 12, 4950.	12.8	15
15	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science, 2021, 374, eabf2911.	12.6	37
16	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. Journal of Clinical Investigation, 2021, 131, .	8.2	20
17	Structures of the HER2â€“HER3â€–NRG1Î² complex reveal a dynamic dimer interface. Nature, 2021, 600, 339-343.	27.8	48
18	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020, 370, .	12.6	508

#	Article	IF	Citations
19	An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms ofCASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2020, 142, 932-947.	1.6	44
20	The structure of a calsequestrin filament reveals mechanisms of familial arrhythmia. Nature Structural and Molecular Biology, 2020, 27, 1142-1151.	8.2	13
21	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature, 2020, 583, 459-468.	27.8	3,542
22	Receptor tyrosine kinase activation: From the ligand perspective. Current Opinion in Cell Biology, 2020, 63, 174-185.	5.4	109
23	PEAK3/C19orf35 pseudokinase, a new NFK3 kinase family member, inhibits CrkII through dimerization. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15495-15504.	7.1	19
24	The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region. Journal of Biological Chemistry, 2019, 294, 13545-13559.	3.4	22
25	The pseudokinase <scp>TRIB</scp> 1 toggles an intramolecular switch to regulate <scp>COP</scp> 1 nuclear export. EMBO Journal, 2019, 38, .	7.8	31
26	Functional role of PGAM5 multimeric assemblies and their polymerization into filaments. Nature Communications, 2019, 10, 531.	12.8	30
27	More than the sum of the parts: Toward fullâ€length receptor tyrosine kinase structures. IUBMB Life, 2019, 71, 706-720.	3.4	20
28	Prospects for pharmacological targeting of pseudokinases. Nature Reviews Drug Discovery, 2019, 18, 501-526.	46.4	83
29	Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Oncogene, 2019, 38, 1936-1950.	5.9	23
30	Feedback regulation of RTK signaling in development. Developmental Biology, 2019, 447, 71-89.	2.0	53
31	Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. Cell Reports, 2018, 22, 2593-2600.	6.4	62
32	Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Structure, 2018, 26, 270-281.e4.	3.3	5
33	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Cancer Cell, 2018, 34, 792-806.e5.	16.8	102
34	Activating HER3 mutations in breast cancer. Oncotarget, 2018, 9, 27773-27788.	1.8	23
35	EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2836-E2845.	7.1	63
36	Switching on BTKâ€”One Domain at a Time. Structure, 2017, 25, 1469-1470.	3.3	1

#	Article	IF	Citations
37	Structural Basis for the Non-catalytic Functions of Protein Kinases. Structure, 2016, 24, 7-24.	3.3	131
38	Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. Molecular and Cellular Biology, 2015, 35, 3083-3102.	2.3	74
39	Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Science Signaling, 2014, 7, ra114.	3.6	98
40	A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochemical Journal, 2014, 457, 323-334.	3.7	241
41	EGFR lung cancer mutants get specialized. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 15169-15170.	7.1	12
42	Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms. Molecular Cell, 2011, 42, 9-22.	9.7	265
43	Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21608-21613.	7.1	278
44	Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment. Cell, 2009, 137, 1293-1307.	28.9	506
45	Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature, 2007, 450, 741-744.	27.8	311
46	hSpry2 Is Targeted to the Ubiquitin-Dependent Proteasome Pathway by c-Cbl. Current Biology, 2003, 13, 308-314.	3.9	136